What is Neutropenia?

Neutropenia is characterized by a significant reduction in neutrophils, which guards against germs and helps fight infections.

White blood cells are made in the bone marrow (a spongy material inside bones) and are an important part of your immune system. Neutrophils make up the majority of white blood cells. They are the first responders and quickly appear at the site of an infection.

Chemotherapy can lower the number of white blood cells in your body. If you have a low number of neutrophils, it is called neutropenia. Having neutropenia makes you more likely to get an infection because the usual mechanism to fight an infection (neutrophils) is not available. If you have neutropenia and a fever (also called febrile neutropenia), it may be the first sign of an infection.

RECOVER is a clinical study for people who are about to start their first treatment for breast cancer. The purpose of this study is to compare eflapegrastim and pegfilgrastim (also known as Neulasta®*) while you receive TC chemotherapy for early-stage breast cancer, by collecting blood samples and will be looking at the number of white blood cells, including neutrophils, being produced by the body.

*Disclaimer Third Parties

All product and company names are trademarks (TM) or registered trademarks (®) of their respective holders. Use of them does not imply any affiliation, approval, license or endorsement by them.

Neulasta® is a registered trademark of Amgen Inc.

Terms of Use

Privacy Policy

Web Site Linking Policy

Eflapegrastim (also known as SPI-2012) is a medication currently being tested and has yet to receive approval from the Food and Drug Administration (FDA).

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

ROL170701700